Entrada Therapeutics, Inc. (TRDA) stock
TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.17−0.27 (-4.96%)
Close on Nov 12, 2026Market cap $201.30MP/E –Yield –
Entrada Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Entrada Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -4058.0%. For fiscal 2025 it was -565.5%, against 31.1% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -565.5% | −596.6 |
| FY2024 | Dec 31, 2024 | 31.1% | +36.3 |
| FY2023 | Dec 31, 2023 | -5.2% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -4391.4% | −1656.9 |
| Q2 FY2026 | Jun 30, 2026 | -4762.0% | −2551.6 |
| Q1 FY2026 | Mar 31, 2026 | -4539.1% | −4454.7 |
| Q4 FY2025 | Dec 31, 2025 | -3014.9% | −3018.0 |
| Q3 FY2025 | Sep 30, 2025 | -2734.4% | −2662.7 |
| Q2 FY2025 | Jun 30, 2025 | -2210.4% | −2268.5 |
| Q1 FY2025 | Mar 31, 2025 | -84.4% | −124.1 |
| Q4 FY2024 | Dec 31, 2024 | 3.0% | +25.8 |
| Q3 FY2024 | Sep 30, 2024 | -71.7% | −152.8 |
| Q2 FY2024 | Jun 30, 2024 | 58.1% | +200.8 |
| Q1 FY2024 | Mar 31, 2024 | 39.7% | +66.2 |
| Q4 FY2023 | Dec 31, 2023 | -22.8% | – |
| Q3 FY2023 | Sep 30, 2023 | 81.1% | – |
| Q2 FY2023 | Jun 30, 2023 | -142.7% | – |
| Q1 FY2023 | Mar 31, 2023 | -26.4% | – |
See a number that looks wrong?